Corvus Pharmaceuticals, Burlingame, CA 94010, United States.
Corvus Pharmaceuticals, Burlingame, CA 94010, United States.
Curr Opin Pharmacol. 2020 Aug;53:126-133. doi: 10.1016/j.coph.2020.08.003. Epub 2020 Sep 29.
The immunosuppressive tumor microenvironment (TME) represents a challenge that all immunotherapies must overcome to enable a robust and durable anti-tumor response. One of the dominant mechanisms of immunosuppression in the TME is hypoxia and the generation of extracellular adenosine [1]. Pioneering work from Drs Ohta and Sitkovsky demonstrating that adenosine signaling through the adenosine 2A receptor (A2AR) inhibits T cells has led to the development of several agents designed to inhibit the production or downstream signaling of adenosine [2,3]. This review will focus on the safety, efficacy, and biomarkers associated with A2AR antagonists in clinical development.
免疫抑制性肿瘤微环境（TME）是所有免疫疗法都必须克服的挑战，以实现强大和持久的抗肿瘤反应。TME 中免疫抑制的主要机制之一是缺氧和细胞外腺苷的产生[1]。Ohta 和 Sitkovsky 博士的开创性工作表明，通过腺苷 2A 受体（A2AR）的腺苷信号抑制 T 细胞，导致开发了几种旨在抑制腺苷产生或下游信号的药物[2,3]。这篇综述将重点介绍临床开发中 A2AR 拮抗剂的安全性、疗效和相关生物标志物。
